These pleiotropic actions have positioned GLP-1 RAs ascornerstone treatment agents, not only for glycemic control but also forcardiovascular risk reduction in high- and very-high-risk individuals living withT2D and obesity [25, 26, 27]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.